Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

Borchmann P, van Meerten T, Iacoboni G, Bories P, Dreger P, Mutsaers P, Gopcsa L, Edinger M, Gergely L, von Tresckow B, Neumeister P, Steiner N, Jäger U, Moreno AT, Griškevičius L, Lemonnier F, van Doesum J, Kersten MJ, Rudzki JD, Shah NN, Orentas R, Friedrichs B, Miltenyi S, Overstijns T, Bürger I, Zadoyan G, Brillant C, Paul P, van Heteren P, Holtkamp S, Vandenberghe P

Open source

DOI: 10.1016/s1470-2045(26)00290-1
Published: 2026 Nov
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00290-1,
  title = {Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.},
  author = {Borchmann P and van Meerten T and Iacoboni G and Bories P and Dreger P and Mutsaers P and Gopcsa L and Edinger M and Gergely L and von Tresckow B and Neumeister P and Steiner N and Jäger U and Moreno AT and Griškevičius L and Lemonnier F and van Doesum J and Kersten MJ and Rudzki JD and Shah NN and Orentas R and Friedrichs B and Miltenyi S and Overstijns T and Bürger I and Zadoyan G and Brillant C and Paul P and van Heteren P and Holtkamp S and Vandenberghe P},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00290-1},
  url = {https://doi.org/10.1016/s1470-2045(26)00290-1}
}

RIS

TY  - JOUR
TI  - Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.
AU  - Borchmann P
AU  - van Meerten T
AU  - Iacoboni G
AU  - Bories P
AU  - Dreger P
AU  - Mutsaers P
AU  - Gopcsa L
AU  - Edinger M
AU  - Gergely L
AU  - von Tresckow B
AU  - Neumeister P
AU  - Steiner N
AU  - Jäger U
AU  - Moreno AT
AU  - Griškevičius L
AU  - Lemonnier F
AU  - van Doesum J
AU  - Kersten MJ
AU  - Rudzki JD
AU  - Shah NN
AU  - Orentas R
AU  - Friedrichs B
AU  - Miltenyi S
AU  - Overstijns T
AU  - Bürger I
AU  - Zadoyan G
AU  - Brillant C
AU  - Paul P
AU  - van Heteren P
AU  - Holtkamp S
AU  - Vandenberghe P
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00290-1
UR  - https://doi.org/10.1016/s1470-2045(26)00290-1
ER  -

APA

P, B., T, V. M., G, I., P, B., P, D., P, M., L, G., M, E., L, G., B, V. T., P, N., N, S., U, J., AT, M., L, G., F, L., J, V. D., MJ, K., JD, R., NN, S., R, O., B, F., S, M., T, O., I, B., G, Z., C, B., P, P., P, V. H., S, H., & P, V. (2026). Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00290-1

Source records

pubmed · retrieved 2026-11-10T14:18:08.436Z